RCTs: Risankizumab as induction therapy for Crohn’s disease.

Risankizumab as induction therapy for Crohn’s disease: results from the phase 3 ADVANCE and MOTIVATE induction trials – The Lancet (link to abstract – $ for full-text)

Related: Risankizumab as maintenance therapy for moderately to severely active Crohn’s disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial – The Lancet (link to abstract – $ for full-text)

Commentary on Twitter

In patients with moderately to severely active Crohn's disease, risankizumab was effective and well tolerated as induction therapy, studies indicate.

Find out more: https://t.co/zg70L8RYka #crohnsdisease pic.twitter.com/9evGJAH8ke

— The Lancet (@TheLancet) June 1, 2022